Emergent BioSolutions | EBS - Pasivo Circulante

Precio De Mercado
8.81
Cambio Diario
0.19 2.20%
Mensual
10.13%
Anual
94.05%
Q2 Expectativa
8.43




Pasivo Circulante Cambio Fecha
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Akebia Therapeutics USD 162.94M 29.56M 2025-12
ALKERMES USD 543.44M 69.08M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amarin USD 194.46M 12.23M 2025-12
ANI Pharmaceuticals USD 278.11M 7.56M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Coherus Biosciences USD 140.39M 231.91M 2025-12
Emergent BioSolutions USD 651.3M 12.7M 2023-12
Exelixis USD 405.64M 31.86M 2025-12
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Heron Therapeutics USD 96.1M 6.39M 2025-12
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
Ironwood Pharmaceuticals USD 242.5M 9.98M 2025-09
Lexicon Pharmaceuticals USD 20.87M 853K 2025-12
Lonza CHF 3.57B 421M 2025-12
Merck USD 28.63B 2.59B 2025-09
Moderna USD 1.99B 306M 2025-12
Myriad Genetics USD 133.8M 14.2M 2025-12
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Pacira USD 120.59M 13.51M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Sanofi EUR 28.35B 3.76B 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
United Therapeutics USD 560.6M 14.3M 2025-12
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Xoma USD 28.3M 6.81M 2025-09